Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15667532 | 0.81 | MAPT (0.39) | SMN1; SMN2MAOAMAOBMAPTHPGD | |
| SCHEMBL949801 | 0.77 | LMNA (0.39) | LMNAL3MBTL1SMN1; SMN2MAOAMAOB | |
| SCHEMBL16586148 | 0.76 | MAOA (0.40) | LMNAL3MBTL1SMN1; SMN2MAOAMAOB | |
| SCHEMBL5540954 | 0.72 | LMNA (0.36) | LMNAL3MBTL1SMN1; SMN2MAOAMAOB | |
| SCHEMBL9427630 | 0.71 | LMNA (0.42) | LMNAL3MBTL1SMN1; SMN2KDM4EGAA | |
| SCHEMBL28617660 | 0.71 | ALDH1A1 (0.43) | LMNAL3MBTL1SMN1; SMN2KDM4EGAA | |
| SCHEMBL9016355 | 0.69 | MAOA (0.35) | LMNAL3MBTL1SMN1; SMN2MAOAMAOB | |
| SCHEMBL8486238 | 0.69 | ADRA2A (0.38) | LMNAKDM4EALDH1A1HSD17B10KMT2A | |
| SCHEMBL465266 | 0.69 | LMNA (0.41) | LMNAL3MBTL1SMN1; SMN2KDM4EGAA | |
| SCHEMBL95521 | 0.69 | LMNA (0.42) | LMNAL3MBTL1SMN1; SMN2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| CN-110545850-A | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB | 2019-12-06 | — | — | CN | disclosed |
| US-20180360974-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2018-12-20 | — | — | US | disclosed |
| WO-2018163131-A1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2018-09-13 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2414339-B1 | KINETIC RESOLUTION OF (4S)-4-PHENYL-3-[5(RS)-(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-1,3 OXAZOLIDIN 2-ONE TO (5S) ISOMER VIA LIPASE CATALYZED ENANTIOSELECTIVE ESTERIFICATION OF THE (5R) ISOMER | LUPIN LTD (IN) | 2013-01-16 | — | — | EP | disclosed |
| US-5475008-A | Selective non-competitive antagonists of n-methyl-d-aspartate receptors | MERCK SHARP & DOHME LIMITED (GB) | 1995-12-12 | — | — | US | disclosed |
| EP-0459561-B1 | Dioxo-tetrahydroquinoline derivatives | MERCK SHARP & DOHME (GB) | 1995-09-20 | — | — | EP | disclosed |
| EP-0614363-A1 | QUINOLONE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1994-09-14 | — | — | EP | disclosed |
| US-5283341-A | Catalytic alkylation | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1994-02-01 | — | — | US | disclosed |
| US-5268378-A | Oxo group in 2 and 4 position | MERCK SHARP & DOHME, LIMITED (GB) | 1993-12-07 | — | — | US | disclosed |
| WO-1993010783-A2 | QUINOLONE DERIVATIVES AND THEIR USE AS AMPA AND NMDA RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1993-06-10 | — | — | WO | disclosed |
| EP-0516982-A1 | Process for producing a heterocyclic tertiary amine | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-12-09 | — | — | EP | disclosed |
| EP-0459561-A2 | Dioxo-tetrahydroquinoline derivatives | MERCK SHARP & DOHME LTD. (GB) | 1991-12-04 | — | — | EP | disclosed |
| US-4214094-A | ANTILIPEMIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-07-22 | — | — | US | disclosed |
| EP-0000644-A2 | Lower cycloalkyl substituted-benzene derivatives, the preparation thereof and their pharmaceutical compositions | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360974-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | LMNA 2176/4885L3MBTL1 3548/4885SMN1; SMN2 1275/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | LMNA 2176/4885L3MBTL1 3548/4885SMN1; SMN2 1275/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | LMNA 2176/4885L3MBTL1 3548/4885SMN1; SMN2 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.